Researcher
Isabelle Vanden Bempt
- Disciplines:Clinical genetics and molecular diagnostics, Medical genomics, Medical transcriptomics
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Member
From24 Nov 2021 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2018 → 23 Nov 2021 - Translational Cell & Tissue Research (Division)
Member
From15 Aug 2003 → 30 Sep 2008
Projects
1 - 4 of 4
- Optical genome mapping for comprehensive genetic analysis of sarcomas in a diagnostic setting.From1 Jan 2023 → TodayFunding: FWO Humanitarian research project Stand up against Cancer
- Whole-genome optical mapping for comprehensive analysis of sarcoma genomes in a diagnostic settingFrom13 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Genomic Medicine: Translation of Whole Genome Analyses to Health GenomicsFrom1 May 2018 → TodayFunding: IOF - mandates, IOF - Industrial Research Fund
- Towards a better selection of systemic treatment for patients with ER-positive HER2-negative breast cancer: the use of prognostic and predictive markers in early and metastatic settingFrom1 May 2017 → 14 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
31 - 40 of 46
- Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis(2010)
Authors: Vanya Van Belle, Ben Van Calster, Isabelle Vanden Bempt, Robert Paridaens, Philippe Moerman, Frédéric Amant, Ann Smeets, Hans Wildiers, Rose Christiaens, Ignace Vergote, et al.
Pages: 4129 - 4134 - T cell/histiocyte rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response(2010)
Authors: Peter Van Loo, Thomas Tousseyn, Daan Dierickx, Isabelle Vanden Bempt, Gregor Verhoef, Peter Marynen, Patrick Matthys, Chris Peeters
Pages: 440 - 448 - Evaluation of the Sysmex pocH-1001 haematology analyser in an outdoor oncology service.(2010)
Authors: Isabelle Vanden Bempt
Pages: 248 - 251 - Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer. Two Case Reports(2009)
Authors: Isabelle Vanden Bempt, Patrick Neven, Philippe Moerman, Ignace Vergote, Frédéric Amant
Pages: 46 - 48 - Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1(2009)
Authors: Patrick Neven, Maria Drijkoningen, Vanya Van Belle, Philippe Moerman, Rose Christiaens, Ann Smeets, Hans Wildiers, Isabelle Vanden Bempt
Pages: 624 - 628 - Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors(2009)
Authors: Vanya Van Belle, Sabine Van Huffel, Frédéric Amant, Ann Smeets, Erik Van Limbergen, Wout Hendrickx, Caroline Weltens, Walter Van den Bogaert, Isabelle Vanden Bempt, Robert Paridaens, et al.
Pages: 349 - 358 - Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors(2009)
Authors: Olivier Brouckaert, Saskia Pintens, Vanya Van Belle, Sabine Van Huffel, Edward Camerlynck, Frédéric Amant, Ann Smeets, Karin Leunen, Erik Van Limbergen, Patrick Berteloot, et al.
Pages: 349 - 358 - Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive(2009)
Authors: Ben Van Calster, Isabelle Vanden Bempt, Jiqiu Cheng, Sabine Van Huffel, Wout Hendrickx, Frédéric Amant, Robert Paridaens, Hans Wildiers, Erik Van Limbergen, Caroline Weltens, et al.
Pages: 181 - 187 - Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing(2008)
Authors: Isabelle Vanden Bempt, Peter Van Loo, Patrick Neven, Ann Smeets, Rose Christiaens, Robert Paridaens
Pages: 4869 - 4874 - Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer(2008)
Authors: Patrick Neven, Ben Van Calster, Isabelle Vanden Bempt, Sabine Van Huffel, Vanya Van Belle, Wout Hendrickx, Julie Decock, Hans Wildiers, Robert Paridaens, Frédéric Amant, et al.
Pages: 153 - 159